Clinaptis Advisors Publishes Institutional Due Diligence on Structure Therapeutics' Aleniglipron

NEW DELHI - Aug. 8, 2026 - PRLog -- Clinaptis Advisors today published a new institutional research report evaluating Structure Therapeutics' (GPCR) lead obesity candidate, aleniglipron, and its competitive positioning within the rapidly evolving oral GLP-1 landscape.

The report reconstructs aleniglipron's Phase 2 ACCESS II efficacy using treatment-regimen assumptions consistent with contemporary regulatory practice, providing a like-for-like comparison with Eli Lilly's orforglipron and oral semaglutide.

"We started this work expecting to find a fatal flaw behind the 16.3 percentage-point headline. We didn't," said Bikram K. Singh, MBBS, Founder of Clinaptis Advisors. "Instead, we found a clinically credible oral GLP-1 whose competitive advantage appears materially narrower than headline comparisons suggest once programs are placed on the same regulatory basis. That distinction changes how we think about valuation—not whether the asset works."

Among the report's principal findings:

• Restates aleniglipron's reported 16.3 percentage-point placebo-adjusted weight-loss result to an estimated 10.2–11.2 percentage points on a treatment-regimen, regulatory-comparable basis.
• Benchmarks the adjustment against Lilly's orforglipron development program, where Phase 2 and Phase 3 data provide a prospective reference for efficacy compression.
• Concludes that the remaining differentiation is narrower than headline comparisons imply, but remains sufficiently competitive that the evidence does not support a fundamental short thesis.
• Argues that the key debate has shifted beyond peak weight loss toward commercial execution, persistence, switching dynamics and long-term market share, with several Phase 3 and commercial catalysts expected during the second half of 2026.

"The investment question is no longer whether aleniglipron produces meaningful weight loss," Singh added. "The more important question is how much commercial differentiation remains once efficacy is measured on a comparable basis—and whether that differentiation is sufficient to justify premium market share."

The full report is available on Clinaptis Research website.
Read the complete analysis at: https://www.clinaptisresearch.com/p/structure-therapeutic...

About Clinaptis Advisors

Clinaptis Advisors is an independent biotechnology research and advisory platform focused on translating clinical development, regulatory science and commercial strategy into actionable investment research for institutional investors. Its work emphasizes primary-source analysis, evidence-based valuation frameworks and catalyst-driven due diligence.